drugset / Trial / NCT07349394

Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants

NCT07349394 ↗

Phase 1 Completed 18 enrolled Vertex Pharmaceuticals Incorporated
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effect of multiple doses of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) on the PK of rosuvastatin and the safety and tolerability of coadministration of VNZ/TEZ/D-IVA with rosuvastatin.

Timeline

Start
2026-01-12
Primary completion
2026-02-28
Completion
2026-03-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule — Oral
Subject VNZ/TEZ/D-IVA Unknown — Oral

Indications